Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin InhibitorJ Lorrain, Stephen E. O'Connor, M. Sainte-Marie et al.|Journal of Pharmacology and Experimental Therapeutics|2003Cited by 23
SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosisC. Visconte, J‐M. Herbert, M. Sainte-Marie et al.|Journal of Thrombosis and Haemostasis|2004Cited by 3
Thrombolysis induced by streptokinase or recombinant plasminogen activator (rt-PA) is improved by SSR182289A, a direct orally active thrombin inhibitor, in rabbit models of thrombosisCaterina Visconte, J. M. Herbert, Paul Schaeffer et al.|Journal of Thrombosis and Haemostasis|2003Cited by 0